16 research outputs found

    Preliminary Trial of Rebamipide for Prevention of Low-Dose Aspirin-Induced Gastric Injury in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study

    Get PDF
    Although low-dose aspirin is widely used, since it is a cheap and effective means of prevention of cardiovascular events, it can cause hemorrhagic gastrointestinal complications. The aim of this study was to evaluate the efficacy of rebamipide in preventing low-dose aspirin-induced gastric injury. A randomized, double-blind, placebo-controlled, crossover trial was performed in twenty healthy volunteers. Aspirin 81 mg was administered with placebo or rebamipide 300 mg three times daily for 7 consecutive days. The rebamipide group exhibited significant prevention of erythema in the antrum compared with the placebo group (p = 0.0393, respectively). Results for the body and fornix did not differ significantly between the placebo and rebamipide groups. In conclusion, short-term administration of low-dose aspirin induced slight gastric mucosal injury in the antrum, but not in the body or fornix. Rebamipide may be useful for preventing low-dose aspirin-induced gastric mucosal injury, especially which confined to the antrum

    Hypoxia-Inducible Factors Activate CD133 Promoter through ETS Family Transcription Factors

    Get PDF
    CD133 is a cellular surface protein that has been reported to be a cancer stem cell marker, and thus it is considered to be a potential target for cancer treatment. However, the mechanism regulating CD133 expression is not yet understood. In this study, we analyzed the activity of five putative promoters (P1-P5) of CD133 in human embryonic kidney (HEK) 293 cells and colon cancer cell line WiDr, and found that the activity of promoters, particularly of P5, is elevated by overexpression of hypoxia-inducible factors (HIF-1 alpha and HIF-2 alpha). Deletion and mutation analysis identified one of the two E-twenty six (ETS) binding sites (EBSs) in the P5 region as being essential for its promoter activity induced by HIF-1 alpha and HIF-2 alpha. In addition, a chromatin imunoprecipitation assay demonstrated that HIF-1 alpha and HIF-2 alpha bind to the proximal P5 promoter at the EBSs. The immunoprecipitation assay showed that HIF-1 alpha physically interacts with Elk1; however, HIF-2 alpha did not bind to Elk1 or ETS1. Furthermore, knockdown of both HIF-1 alpha and HIF-2 alpha resulted in a reduction of CD133 expression in WiDr. Taken together, our results revealed that HIF-1 alpha and HIF-2 alpha activate CD133 promoter through ETS proteins

    Effect of HIFs or ETS knockdown on CD133 promoter activity and expression in WiDr cells.

    No full text
    <p>(A) P5 −98 bp promoter activity under knockdown of HIF-1α and HIF-2α. (B) P5 −98 bp promoter activity under knockdown of ETS families. (C) P5 −98 bp promoter activity after overexpression of HIF-1α and HIF-2α 24 hrs after knockdown of HIF-1α and HIF-2α under normoxia and hypoxia. (D) Quantitative real-time reverse-transcription PCR (qRT-PCR) analysis of CD133 under knockdown of HIF-1α and HIF-2α. *<i>P</i><0.05 vs. control siRNA (siCont). (E) Western blot analysis of HIF-1α and HIF-2α and CD133 under knockdown of HIF-1α and HIF-2α. β-actin is an internal control.</p

    Binding of HIFs to CD133 P5 proximal promoter and ETS-family proteins.

    No full text
    <p>(A) Chromatin immunoprecipitation (ChIP) assay showing the binding of O<sub>2</sub>-stable HIF-1α and HIF-2α (HIF-1α-P/A and HIF-2α-P/A, respectively) to the CD133 P5 promoter (between −98 bp and +10 bp) in WiDr cells. (B) IP-western blot analysis showing the binding of HIF-1α-P/A and HIF-2α-P/A to ETS1 or Elk1 using human embryonic kidney (HEK) 293 cells (left) and WiDr cells (right). (C) Luciferase activity of P5 −98 bp promoter in HEK293 cells after overexpression of HIF-1α together with the knockdown of Elk1. *<i>P</i><0.05 vs. HIF-1α overexpression. (D) IP-western blot analysis showing the binding of HIF-1α to Elk1 under normoxia and hypoxia in HEK293 cells.</p
    corecore